Overview
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, primarily engaged in developing innovative therapies in the fields of endocrinology, oncology, and central nervous system disorders. The company employs its proprietary TransCon technology to create prodrugs that provide sustained release of active drugs, offering therapeutic benefits with less frequent dosing. Key projects include treatments for growth hormone deficiency and hypoparathyroidism, such as their flagship product, TransCon hGH, a once-weekly prodrug for growth hormone deficiency that has shown promise in clinical trials. Ascendis Pharma also has significant initiatives underway in developing treatments for achondroplasia and other rare diseases, positioning itself as a notable player in the global pharmaceutical landscape focused on addressing unmet medical needs.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is 490.75 MM.
- The operating income for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -253.53 MM.
- The net income for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -271.15 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 490.75 | -253.53 | -271.15 |
| 2025-03-31 | 368.70 | -333.83 | -341.68 |
| 2024-12-31 | 363.64 | -278.76 | -378.08 |
| 2024-09-30 | 327.43 | -315.76 | -426.49 |
| 2024-06-30 | 317.63 | -353.42 | -489.52 |
| 2024-03-31 | 329.02 | -361.00 | -501.57 |
| 2023-12-31 | 266.72 | -455.54 | -481.45 |
| 2023-09-30 | 151.91 | -566.32 | -601.99 |
| 2023-06-30 | 119.17 | -576.41 | -608.72 |
| 2023-03-31 | 77.94 | -577.47 | -568.61 |
| 2023-01-01 | 51.17 | -561.81 | -583.19 |
| 2022-09-30 | 33.17 | -527.01 | -481.84 |
| 2022-06-30 | 19.00 | -479.44 | -393.23 |
| 2022-03-31 | 13.86 | -455.17 | -446.28 |
| 2021-12-31 | 7.78 | -451.79 | -383.58 |
| 2021-09-30 | 3.42 | -434.85 | -416.48 |
| 2021-06-30 | 5.06 | -416.75 | -457.87 |
| 2021-03-31 | 5.47 | -382.06 | -418.43 |
| 2020-12-31 | 6.95 | -330.62 | -418.95 |
| 2020-09-30 | 8.93 | -299.82 | -360.35 |
| 2020-06-30 | |||
| 2020-03-31 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | -6.53 | |
| 2024-09-30 | -7.47 | -7.47 |
| 2024-06-30 | -8.62 | -8.62 |
| 2024-03-31 | -8.88 | -8.88 |
| 2023-12-31 | -8.55 | |
| 2023-09-30 | -10.72 | -10.72 |
| 2023-06-30 | -10.87 | -10.87 |
| 2023-03-31 | -10.17 | -10.17 |
| 2023-01-01 | -10.40 | |
| 2022-09-30 | -8.56 | -8.56 |
| 2022-06-30 | -7.02 | -7.02 |
| 2022-03-31 | -8.04 | -8.04 |
| 2021-12-31 | -7.00 | |
| 2021-09-30 | -7.72 | -7.72 |
| 2021-06-30 | -8.56 | -8.56 |
| 2021-03-31 | -8.04 | -8.04 |
| 2020-12-31 | -8.28 | |
| 2020-09-30 | -7.33 | -7.33 |
| 2020-06-30 | -5.50 | -5.50 |
| 2020-03-31 | -4.78 | -4.78 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -164.96 MM.
- The cash from investing activities for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -5.93 MM.
- The cash from financing activities for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is 416.92 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -164.96 | -5.93 | 416.92 |
| 2025-03-31 | -218.93 | -0.98 | 407.48 |
| 2024-12-31 | -306.20 | 6.88 | 443.93 |
| 2024-09-30 | -261.49 | 13.91 | 437.79 |
| 2024-06-30 | -330.08 | 36.63 | 153.27 |
| 2024-03-31 | -421.90 | 82.98 | 153.42 |
| 2023-12-31 | -467.36 | 286.47 | 134.29 |
| 2023-09-30 | -566.58 | 279.03 | 141.70 |
| 2023-06-30 | -540.69 | 270.90 | -1.74 |
| 2023-03-31 | -511.95 | 233.84 | -1.66 |
| 2023-01-01 | -495.70 | 61.73 | 396.77 |
| 2022-09-30 | -477.32 | -49.39 | 374.80 |
| 2022-06-30 | -476.01 | -43.07 | 745.48 |
| 2022-03-31 | -466.82 | -41.92 | 749.10 |
| 2021-12-31 | -417.65 | -110.58 | 351.39 |
| 2021-09-30 | -384.67 | -69.79 | 382.33 |
| 2021-06-30 | -344.97 | -65.80 | 596.39 |
| 2021-03-31 | -286.38 | -315.18 | 603.79 |
| 2020-12-31 | -271.55 | -291.20 | 602.65 |
| 2020-09-30 | -230.45 | -221.20 | 596.60 |
| 2020-06-30 | |||
| 2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2023-01-01 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 | |||
| 2020-06-30 | |||
| 2020-03-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2023-01-01 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 | ||
| 2020-06-30 | ||
| 2020-03-31 |
Management Effectiveness
- The roa for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.62.
- The roe for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.70.
- The roic for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.45.
- The croic for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.01.
- The ocroic for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.29.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2025-03-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2024-12-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2024-09-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2024-06-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2024-03-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2023-12-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2023-09-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2023-06-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2023-03-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2023-01-01 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2022-09-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2022-06-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2022-03-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2021-12-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2021-09-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2021-06-30 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2021-03-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2020-12-31 | -0.62 | -0.70 | -0.45 | -0.01 | -0.29 |
| 2020-09-30 | -0.49 | -0.55 | -0.37 | 0.11 | -0.23 |
| 2020-06-30 | -0.34 | -0.39 | -0.51 | -0.88 | -0.45 |
| 2020-03-31 | -0.30 | -0.32 | -0.39 | -0.28 | -0.31 |
Gross Margins
- The gross margin for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -16.42.
- The net margin for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -60.26.
- The operating margin for Ascendis Pharma A/S - Depositary Receipt (Common Stock) as of June 30, 2025 is -47.55.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | -16.42 | -60.26 | -47.55 |
| 2025-03-31 | -16.42 | -60.26 | -47.55 |
| 2024-12-31 | -16.42 | -60.26 | -47.55 |
| 2024-09-30 | -16.42 | -60.26 | -47.55 |
| 2024-06-30 | -16.42 | -60.26 | -47.55 |
| 2024-03-31 | -16.42 | -60.26 | -47.55 |
| 2023-12-31 | -16.42 | -60.26 | -47.55 |
| 2023-09-30 | -16.42 | -60.26 | -47.55 |
| 2023-06-30 | -16.42 | -60.26 | -47.55 |
| 2023-03-31 | -16.42 | -60.26 | -47.55 |
| 2023-01-01 | -16.42 | -60.26 | -47.55 |
| 2022-09-30 | -16.42 | -60.26 | -47.55 |
| 2022-06-30 | -16.42 | -60.26 | -47.55 |
| 2022-03-31 | -16.42 | -60.26 | -47.55 |
| 2021-12-31 | -16.42 | -60.26 | -47.55 |
| 2021-09-30 | -16.42 | -60.26 | -47.55 |
| 2021-06-30 | -16.42 | -60.26 | -47.55 |
| 2021-03-31 | -16.42 | -60.26 | -47.55 |
| 2020-12-31 | -16.42 | -60.26 | -47.55 |
| 2020-09-30 | -12.57 | -40.38 | -33.59 |
| 2020-06-30 | -2.09 | -31.35 | -32.70 |
| 2020-03-31 | -4.65 | -22.35 | -23.92 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1612042 |
Industry Groups
| SIC 2834 - Pharmaceutical Preparations |
